– USA, CA – OncoCyte Corporation, a cancer diagnostics company and a member of the BioTime, Inc. (NYSE MKT:BTX) family of companies, announced today that Andy Arno has been appointed to the Company’s Board of Directors.
Andy Arno, 56, brings to OncoCyte a wealth of knowledge from his 30 years of capital markets experience working with emerging growth companies. He is currently Vice Chairman of “The Special Equities Group” at Chardan Capital Markets, LLC, a privately held investment banking firm. He was previously Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., as well as President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He also served as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of its parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the boards of Asterias Biotherapeutics (NYSE MKT:AST) and Smith Micro Software, Inc., and is a graduate of George Washington University.
“OncoCyte is uniquely positioned to advance in the non-invasive diagnostic market targeting lung, breast and bladder cancer. Andy’s wealth of experience in the capital markets and advising emerging growth companies will be invaluable as we develop and execute strategies to fund OncoCyte’s development and growth. We look forward to having Andy Arno assist us with his vision, leadership and expertise in support of the Company’s mission as we build our diagnostic product pipeline and team,” said William Annett, OncoCyte’s Chief Executive Officer.
About OncoCyte’s Cancer Diagnostics Program
Positive clinical results from two prospective clinical studies of PanC-Dx™ were presented at the annual meeting of the American Association for Cancer Research (AACR) in April 2015. PanC-Dx™ is OncoCyte’s class of proprietary, non-invasive cancer diagnostic tests. The AACR presentation featured the high levels of sensitivity and specificity demonstrated for PanC-Dx™ when used for the non-invasive detection of the most common type of bladder cancer, urothelial carcinoma (UC). These clinical results were announced in collaboration with investigators from a Leading Medical Institution.
In addition, initial data from a large, prospective clinical study showed the potential of PanC-Dx™ as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data revealed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data were presented in April 2015 at the annual meeting of the American Association for Cancer Research (AACR).
About OncoCyte Corporation
OncoCyte, a majority-owned subsidiary of BioTime, Inc., is developing novel products for the diagnosis and treatment of cancer in order to improve the quality and length of life of cancer patients. Based on large unmet need, market size, and data generated thus far from patient sample screening, OncoCyte is initially focusing its efforts on developing non-invasive diagnostic products for use in detecting lung, bladder, and breast cancers. OncoCyte is developing a class of non-invasive cancer diagnostics based on a proprietary set of cancer markers characterized, in part, by broad gene expression patterns in numerous cancer types. The Company’s biomarkers were discovered as a result of ongoing research within OncoCyte and BioTime on the gene expression patterns associated with embryonic development. This research has demonstrated that many of the same genes associated with normal growth during embryonic development are abnormally reactivated by cancer cells. These genes regulate such diverse processes as cell proliferation, cell migration, and blood vessel formation. Many of these genes have not been previously associated with cancer. Moreover, expression of a large subset of these genes is conserved across numerous cancer types (e.g., cancers of the breast, colon, ovaries, etc.), suggesting that these genes may control fundamental processes during cancer growth and progression. In addition to their potential value in developing diagnostic biomarkers, an understanding of the pattern of expression of these genes may also enable the development of powerful new cancer therapeutics that target rapidly proliferating cancer cells.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.